Introduction
The clinical utility of any cancer treatment is de®ned by both its antitumoral potency and its therapeutic index between cancerous and normal cells. Chemotherapy for metastatic solid tumors generally fails due to an insucient therapeutic index and/or insucient antitumoral potency. Although standard agents target a variety of dierent structures within cancer cells, almost all of them are thought to kill cancer cells through the induction of apoptosis. As a result, apoptosis-resistant clones develop following standard therapies, even if numerous high-dose chemotherapeutic agents are used in combination. Novel therapeutic approaches must therefore have not only greater potency and greater selectivity than currently available treatments, they should also have novel mechanisms of action that will not be subject to cross-resistance with existing approaches (i.e. ecacy should not be exclusively dependent on apoptosis induction in cancer cells).
Replication-selective oncolytic viruses (virotherapy) appear to have these characteristics. Viruses have evolved to infect cells, replicate, induce cell death, release of viral particles, and ®nally to spread in human tissues. Replication in tumor tissue leads to ampli®cation of the input dose at the tumor site, while a lack of replication in normal tissues can result in ecient clearance and reduced toxicity (Figure 1 ). Selective replication within tumor tissue can theoretically increase the therapeutic index of these agents dramatically. In addition, viruses kill cells by a number of unique mechanisms. In addition to direct lysis at the conclusion of the replicative cycle, viruses can kill cells through expression of toxic proteins, induction of both in¯ammatory cytokines and T-cell-mediated immunity, and enhancement of cellular-sensitivity to their eects. Therefore, since activation of classical apoptosis pathways in the cancer cell is not the exclusive mode of killing, cross-resistance with standard chemotherapeutics or radiotherapy is much less likely to occur.
Revolutionary advances in molecular biology and genetics have led to a fundamental understanding of both (1) the replication and pathogenicity of viruses and (2) carcinogenesis. These advances have allowed novel agents to be engineered to enhance their safety and/or their antitumoral potency. Over the past decade, genetically-engineered viruses in development have included adenoviruses, herpesviruses and vaccinia. Viruses with inherent tumor-selectivity have been characterized and include reovirus, autonomous parvoviruses, Newcastle disease virus, measles virus strains and vesicular stomatitis virus (Kirn, 2000a) . Each of these agents has shown tumor selectivity in vitro and/or in vivo, with many of these agents following intratumoral, intraperitoneal and/or intravenous routes of administration.
Although preclinical data reported with these agents has been encouraging, many critical questions have awaited results from clinical trials. Viral agents like adenovirus have complex biologies, potentially including species-speci®c interactions with host cell machinery and/or immune response eectors (Wold et al., 1994; Sparer et al., 1996) . Antitumoral ecacy and safety studies with these viruses have been performed in rodent or primate models, and all published animal tumor model data with replication-selective adenoviruses has come from immunode®cient mouse-human tumor xenograft models (Rodriguez et al., 1997; Heise et al., 1999a,b) . Therefore, data from cancer patients has been eagerly awaited. Now, after over 5 years of clinical research with dl1520, roughly 15 clinical trials have been completed and recently analysed involving approximately 250 patients. This article will review the discovery and development of replication-selective oncolytic adenoviruses, with an emphasis on recently-acquired data from phase I and II clinical trials. The goal will be to summarize (1) the genetic targets and mechanisms of selectivity for these agents; (2) clinical trial data and what it has taught us to date about the promise but also the potential hurdles to be overcome with this approach; (3) future approaches to overcome these hurdles.
Attributes of replication-selective adenoviruses for cancer treatment
A number of ecacy, safety and manufacturing issues need to be assessed when considering a virus species for development as an oncolytic therapy (Kirn, 2000a) . First, by de®nition the virus must replicate in and destroy human tumor cells. An understanding of the genes modulating infection, replication or pathogenesis is necessary for rational engineering of the virus. Since most solid human tumors have relatively low growth fractions, the virus should infect both cycling and noncycling cells. In addition, receptors for viral entry must be expressed on the target tumor(s) in patients Oncogene (2000) 19, 6660 ± 6669 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc *Correspondence: D Kirn (Wickham et al., 1996) . From a safety standpoint, the parental wildtype virus should ideally cause only mild, well-characterized human disease(s). Non-integrating viruses have potential safety advantages, as well. A genetically-stable virus is desirable from both safety and manufacturing standpoints. Finally, the virus must be amenable to high-titer production and puri®cation under Good Manufacturing Practices (GMP) guidelines for clinical studies. Human adenoviruses have these characteristics and are therefore excellent oncolytic virus candidates .
Biology of human adenovirus
Adenovirus biology is reviewed in detail elsewhere (Shenk, 1996) . Roughly 50 dierent serotypes of human adenovirus have been discovered; the two most commonly studied are types 2 and 5 (group C). Adenoviruses have linear, double-stranded DNA genomes of approximately 38 kB. The capsid is nonenveloped and is comprised of the structural proteins hexon, ®ber (binds coxsackie and adenovirus receptor-CAR), penton (binds a v b 3,5 integrins for virus inter- Oncogene Oncolytic adenovirus review D Kirn nalization). The adenovirus life-cycle includes the following steps: (1) virus entry into the cell following CAR and integrin binding, (2) release from the endosome and subsequent entry into the nucleus, (3) expression of early region gene products, (4) cell entry into S phase, (5) prevention of p53-dependent and -independent apoptosis, (6) shut-o of host cell protein synthesis, (7) viral DNA replication, (8) viral structural protein synthesis, (9) virion assembly in the nucleus, (10) cell death and (11) virus release. The E3 region encodes a number of gene products responsible for immune response evasion (Wold et al., 1995) (Dimitrov et al., 1997) . The gp19kD protein inhibits MHC-class I expression on the cell surface (i.e. avoidance of cytotoxic T-lymphocyte-mediated killing) (Hermiston et al., 1993) , and the E3 10.4/14.5 kD (RID complex) and 14.7 kD proteins inhibit apoptosis mediated by FasL or tumor necrosis factor (TNF) (Dimitrov et al., 1997; Shisler et al., 1996) .
Mechanisms of adenovirus-mediated cell killing
Adenovirus replication within a target tumor cell can lead to cell destruction by several mechanisms (Table  1 ). Viral proteins expressed late in the course of infection are directly cytotoxic, including the E3 11.6 kD adenovirus death protein (Tollefson et al., 1996) and E4ORF4 [Branton, 1999 . Deletion of these gene products results in a signi®cant delay in cell death. In addition, E1A expression early during the adenovirus life-cycle induces cell sensitivity to tumor necrosis factor (TNF)-mediated killing (Gooding, 1994) . This eect is inhibited by the E3 proteins 10.4/ 14.5 and 14.7; deletion of these E3 proteins leads to an increase in TNF expression in vivo and enhanced cell sensitivity to TNF (Sparer et al., 1996) . Finally, viral replication in and lysis of tumor cells has been shown to promote the induction of cell-mediated immunity to uninfected tumor cells in model systems with other viruses (Toda et al., 1999; Martuza, 2000) ; whether this will occur in patients and with adenovirus remains to be determined.
Approaches to optimizing tumor-selective adenovirus replication
Two broad approaches are currently being used to engineer tumor-selective adenovirus replication. One is to limit the expression of the E1A gene product to tumor tissues through the use of tumor-and/or tissuespeci®c promoters. E1A functions to stimulate S phase entry and to transactivate both viral and cellular genes that are critical for a productive viral infection (Whyte et al., 1988) . A second broad approach to optimizing tumor selectivity is to delete gene functions that are critical for ecient viral replication in normal cells but are expendable in tumor cells (described below).
Tissue-or tumor-speci®c promoters can replace endogenous viral sequences in order to restrict viral replication to a particular target tissue. For example, the prostate-speci®c antigen (PSA) promoter/enhancer element has been inserted upstream of the E1A gene; the result is that viral replication correlates with the level of PSA expression in a given cell (Rodriguez et al., 1997) . This virus, CN706 (Calydon Pharmaceuticals, CA, USA), is currently in a phase I clinical trial of intratumoral injection for patients with locallyrecurrent prostate carcinoma. A second prostatespeci®c enhancer sequence has subsequently been inserted upstream of the E1B region (Yu et al., 1999) ; the use of these two prostate-speci®c enhancer elements to drive separate early gene regions has led to improved selectivity over the ®rst generation virus (Yu et al., 1999) . A similar approach has been pursued by other groups using tissue-speci®c promoters to drive E1A expression selectively in speci®c carcinomas (e.g. alpha-fetoprotein, carcinoembryonic antigen, MUC-1) (Hallenbeck, 1999; Kurihara et al., 2000) .
A second general approach is to complement loss-offunction mutations in cancers with loss-of-function mutations within the adenovirus genome. Many of the same critical regulatory proteins that are inactivated by viral gene products during adenovirus replication are also inactivated during carcinogenesis (Barker and Berk, 1987; Nielsch et al., 1991; Sherr, 1996; Olson and Levine, 1994) . Because of this convergence, the deletion of viral genes that inactivate these cellular regulatory proteins can be complemented by genetic inactivation of these proteins within cancer cells (Heise et al., 1997b; Kirn et al., 1998a) . The deletion approach was ®rst described by Martuza et al. (1991) with herpesviruses; the thymidine kinase gene (dlsptk) and subsequently the ribonucleotide reductase gene (G207) were deleted (Mineta et al., 1995) . Two adenovirus deletion mutation approaches have subsequently been described (see below).
E1A-CR2 region deletion mutants
Mutants in the E1A conserved region 2 (CR2) are defective in pRB binding (Whyte et al., 1989; Hu et al., 1990) . These viruses are being evaluated for use against tumors with pRB pathway abnormalities (e.g. loss of the G1-S checkpoint) (Heise et al., 2000a; Kirn et al., 1998a; Fueyo et al., 2000) . The delta-24 E1A-CR2 (Fueyo et al., 2000) . With dl922/947, a very similar E1A-CR2 mutant, S phase induction and viral replication are signi®cantly inhibited in quiescent normal cells, whereas replication and cytopathic eects proceed eciently in tumor cells; interestingly, dl922/ 947 demonstrates signi®cantly greater potency than dl1520 both in vitro and in vivo (Kirn et al., 1998a; Heise et al., 2000a) , and in a nude mouse-human tumor xenograft model, intravenously administered dl922/947 had signi®cantly superior ecacy to even wildtype adenovirus (Heise et al., 2000a) . Unlike the complete deletion of E1B-55 kD in dl1520, these mutations in E1A are targeted to a single conserved region and may therefore leave intact other important functions of the gene product; therefore, viral potency is not attenuated.
E1B-55 kD gene deletion mutant: dl1520 dl1520 (Onyx-015) was the ®rst adenovirus described to mirror the gene deletion approach pioneered by Martuza with herpesvirus. Bischo et al. (1996) hypothesized that an adenovirus with deletion of a gene encoding a p53-binding protein, E1B-55 kD, would be selective for tumors that already had inhibited or lost p53 function. p53 function is lost in the majority of human cancers through mechanisms including gene mutation, overrexpression of p53-binding inhibitors (e.g. mdm2, human papillomavirus E6) and loss of the p53-inhibitory pathway modulated by p14 ARF (Schener et al., 1991; Zhang et al., 1998; Hollstein et al., 1991) . However, the precise role of p53 in the inhibition of adenoviral replication has not been de®ned to date. In addition, other adenoviral proteins also have direct or indirect eects on p53 function (e.g. E4orf6, E1B 19 kD, E1A) (Dobner et al., 1996) . Finally, E1B-55 kD itself has important viral functions that are unrelated to p53 inhibition (e.g. viral mRNA transport, host cell protein synthesis shut-o) (Yew et al., 1994) (Figure 2 ).
Not surprisingly, therefore, the role of p53 in the replication-selectivity of dl1520 has been dicult to con®rm despite extensive in vitro experimentation by many groups. E1B-55 kD gene deletion was associated with decreased replication and cytopathogenicity in p53(+) tumor cells versus matched p53(7) tumor cells, relative to wildtype adenovirus, in RKO and H1299 cells (Bischo et al., 1996; Harada and Berk, 1999; Rogulski et al., 2000) . However, con¯icting data on the role of p53 in modulating dl1520 replication and/or c.p.e. has come from dierent cell systems; no p53 eect was demonstrated in matched U2OS cells, for example (Rothmann et al., 1998) . It is clear that many other cellular factors independent of p53 play critical roles in determining the sensitivity of cells to dl1520 (Ries et al., 2000; Harada and Berk, 1999; Heise et al., 1997a; Ornelles, 1997, 1998) . Clinical trials were ultimately necessary to determine the selectivity and clinical utility of dl1520 (see below).
Clinical trial results with replication-competent adenoviruses in cancer patients
Clinical trial results with wild-type adenovirus: flawed study design
Over the last century a diverse array of viruses were injected into cancer patients by various routes, including adenovirus, Bunyamwara, coxsackie, dengue, feline panleukemia, Ilheus, mumps, Newcastle Disease virus, vaccinia and West Nile (Kirn, 2000a; Southam and Moore, 1952; Asada, 1974; Smith et al., 1956) . These studies illustrated both the promise and the hurdles to overcome with oncolytic viral therapy. Unfortunately, these previous clinical studies were not performed to current clinical research standards, and therefore none give interpretable and de®nitive results. At best, these studies are useful in generating hypotheses that can be tested in future trials.
Although suering from many of the trial design aws listed below, a trial with wild-type adenovirus is one of the most useful for hypothesis generation but also for illustrating how clinical trial design¯aws severely curtail the utility of the study results. The knowledge that adenoviruses could eradicate a variety of tumor cells in vitro led to a clinical trial in the 1950's with wild-type adenovirus. Ten dierent serotypes were used to treat 30 cervical cancer patients (Smith et al., 1956) . Forty total treatments were administered by either direct intratumoral injection (n=23), injection into the artery perfusing the tumor (n=10), treatment by both routes (n=6) or intravenous administration (n=1). Characterization of the material injected into patients was minimal. The volume of viral supernatant injected is reported, but actual viral titers/doses are not; injection volumes (and by extension doses) varied greatly. When possible, the patients were treated with a serotype to which they had no neutralizing antibodies present. Corticosteroids were administered as nonspeci®c immunosuppressive agents in roughly half of the cases. Therefore, no two patients were treated in identical fashion.
Nevertheless, the results are intriguing. No signi®-cant local or systemic toxicity was reported. This relative safety is notable given the lack of pre-existing immunity to the serotype used and concomitant corticosteroid use in many patients. Some patients reported a relatively mild viral syndrome lasting 2 ± 7 days (severity not de®ned); this viral syndrome resolved spontaneously. Infectious adenovirus was recovered from the tumor in two-thirds of the patients for up to 17 days post-inoculation. Two-thirds of the patients had a`marked to moderate local tumor response' with necrosis and ulceration of the tumor (de®nition of`response' not reported). None of the seven control patients treated with either virus-free tissue culture¯uid or heatinactivated virus had a local tumor response (statistical signi®cance not reported). Therefore, clinically evident tumor necrosis was only reported with viable virus. Neutralizing antibodies increased within 7 days after administration. Although the clinical bene®t to these patients is unclear, and all patients eventually had tumor progression and died, this study did demonstrate that wildtype adenoviruses can be safely administered to patients and that these viruses can replicate and cause necrosis in solid tumors despite a humoral immune response. The maximally-tolerated dose, dose-limiting toxicity, objective response rate and time to tumor progression, however, remain unknown for any of these serotypes by any route of administration.
A novel staged approach to clinical research with replication-selective viruses: the example of dl1520 (Onyx-015)
For the ®rst time since viruses were ®rst conceived as agents to treat cancer over a century ago, we now have de®nitive data from numerous phase I and II clinical trials with a well-characterized and well-quantitated virus. dl1520 (Onyx-015, now CI-1042, P®zer, Inc.) is a novel agent with a novel mechanism of action. This virus was to become the ®rst virus to be used in humans that had been genetically-engineered for replication-selectivity.
We predicted that both toxicity and ecacy would be dependent on multiple factors including (1) the inherent ability of a given tumor to replicate and shed the virus, (2) the location of the tumor to be treated (e.g. intracranial vs peripheral) and (3) the route of administration of the virus. In addition, we felt it would be critical to obtain biological data on viral replication, antiviral immune responses and their relationship to antitumoral ecacy in the earliest phases of clinical research. We therefore designed and implemented a novel staged clinical research and development approach with this virus (Figure 3 ). The goal of this approach was to sequentially increase systemic exposure to the virus only after safety with more localized delivery had been demonstrated. Following demonstration of safety and biological activity by the intratumoral route, trials were sequentially initiated to study intracavitary instillation (initially intraperitoneal), intra-arterial infusion (initially hepatic artery) and eventually intravenous administration. In addition, only patients with advanced and incurable cancers were initially enrolled on trials. Only after safety had been demonstrated in terminal cancer patients were trials initiated for patients with premalignant conditions. Finally, clinical trials of combinations with chemotherapy were initiated only after the safety of dl1520 as a single agent had been documented by the relevant route of administration.
Results from clinical trials with dl1520 (Onyx-015, or CI-1042)
Toxicity
No maximally-tolerated dose or dose-limiting toxicities were identi®ed at doses up to 2610 12 particles administered by intratumoral injection. Flu-like symptoms and injection-site pain were the most common associated toxicities . This safety is remarkable given the daily or even twice-daily dosing that was repeated every 1 ± 3 weeks in the head and neck region or pancreas (Nemunaitis et al., 2000b) .
Intraperitoneal, intra-arterial and intravenous administration were also remarkably well-tolerated, in general. Intraperitoneal administration was feasible at doses up to 10 13 particles divided over ®ve days (Vasey et al., 2000) . The most common toxicities included fever, abdominal pain, nausea/vomiting and bowel motility changes (diarrhea, constipation). The severity of the symptoms appeared to correlate with tumor burden. Patients with heavy tumor burdens reached a maximally-tolerated dose at 10 12 particles (dose-limiting toxicities were abdominal pain and diarrhea), whereas patients with a low tumor burden tolerated 10 13 without signi®cant toxicity.
No dose-limiting toxicities were reported following repeated intravascular injection at doses up to 2610 12 particles (hepatic artery) (Reid et al., 2000) or 2610 13 particles (intravenous) (Nemunaitis et al., 2000a) . Fever, chills and asthenia following intravascular injection were more common and more severe than after intratumoral injections (grade 2 ± 3 fever and chills vs grade 1). Dose-related transaminitis was reported infrequently. The transaminitis was typically transient (510 days) and low-grade (grade 1 ± 2) and was not clinically-relevant. Further dose escalation was limited by supply of the virus.
Viral replication
Viral replication has been documented at early timepoints after intratumoral injection in head and neck cancer patients (Figure 4) (Nemunaitis et al., 2000b,c) . Roughly 70% of patients had evidence of replication on days 1 ± 3 after their last treatment. In contrast, day 14 ± 17 samples were uniformly negative. Intratumoral injection of liver metastases (primarily colorectal) led to similar results at the highest doses of a phase I trial. Patients with injected pancreatic tumors, in contrast, showed no evidence of viral replication by plasma PCR or ®ne needle aspiration. Similarly, intraperitoneal dl1520 could not be shown to reproducibly infect ovarian carcinoma cells within the peritoneum. Therefore, dierent tumor types can vary dramatically in their permissiveness for viral infection and replication.
Proof-of-concept for tumor infection following intraarterial (Reid et al., 2000) or intravenous (Nemunaitis et al., 2000a) administration with human adenovirus has also been achieved. Approximately half of the roughly 25 patients receiving hepatic artery infusions of 2610 12 particles were positive by PCR 3-5 following treatment. Patients with elevated neutralizing antibody titers prior to treatment were substantially less likely to have evidence of viral replication 3 ± 5 days posttreatment. Three of four patients with metastatic carcinoma to the lung treated intravenously with 52610 12 particles were positive for replication by PCR on day 3 (+1). Therefore, it is feasible to infect distant tumor nodules following intravenous or intraarterial administration.
Immune response
Neutralizing antibody titers to the coat (Ad5) of dl1520 were positive but relatively low in roughly 50 ± 60% of all clinical trial patients at baseline (Nemunaitis et al., 2000b) . Antibody titers increased uniformly following administration of dl1520 by any of the routes tested, in some cases to levels 41 : 80 000. Antibody increases occurred regardless of evidence for replication or shedding into the bloodstream (Nemunaitis et al., 2000b) . Acute in¯ammatory cytokine levels were determined prior to treatment (by hepatic artery infusion), 3 h post-and 18 h post-treatment: IL-1, IL-6, IL-10, interferon-gamma, tumor necrosis factor. Signi®cant increases were demonstrated within 3 h for IL-1, IL-6, tumor necrosis factor and to a lesser extent interferon-gamma; all cytokines were back down to pretreatment levels by 18 h (Reid et al., 2000) . In contrast, IL-10 did not increase until 18 h.
Efficacy with dl1520 (Onyx-015) as a single agent Two Phase II trials enrolled a total of 40 patients with recurrent head and neck cancer (Nemunaitis et al., 2000b,c) . Tumors were treated very aggressively with 6 ± 8 daily needle passes for 5 consecutive days (30 ± 40 needle passes per 5 day cycle; n=30) and 10 ± 15 per day on a second trial (50 ± 75 needle passes per cycle; n=10). The median tumor volume on these studies was approximately 25 cm 3 ; an average cm 3 of tumor therefore received an estimated 4 ± 5 needle passes per cycle. Despite the intensity of this local treatment, the uncon®rmed response rate at the injected site was only 14% and the con®rmed local response rate was 510%. Interestingly, there was no correlation between evidence of antitumoral activity and neutralizing antibody levels at baseline or post-treatment (Nemunaitis et al.,
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Oncolytic adenovirus review D Kirn 2000b) . No objective responses were demonstrated in patients with tumor types that could not be so aggressively injected (due to their deep locations), although some evidence of minor shrinkage or necrosis was obtained. In summary, single agent responses across all studies were rare, and therefore combinations with chemotherapy were explored.
Efficacy in combination with chemotherapy: potential synergy discovered
Evidence for a potentially-synergistic interaction between adenoviral therapy and chemotherapy has been obtained on multiple trials. Encouraging clinical data has been obtained in patients with recurrent head and neck cancer treated with intratumoral dl1520 in combination with intravenous cisplatin and 5-¯uorour-acil (Khuri et al., 2000) . Thirty-seven patients were treated and 19 responded (54%, intent-to-treat; 63%, evaluable); this compares favorably with response rates to chemotherapy alone in previous trials (30 ± 40%, generally). The time-to-tumor progression was also superior to previously reported studies. However, comparisons to historical controls are unreliable. We therefore used patients as their own controls whenever possible (n=11 patients). Patients with more than one tumor mass had a single tumor injected with dl1520 while the other mass(es) was left uninjected. Since both masses were exposed to chemotherapy, the eect of the addition of viral therapy to chemotherapy could be assessed. The dl1520-injected tumors were signi®cantly more likely to respond (P=0.017) and less likely to progress (P=0.06) than were non-injected tumors. Non-injected control tumors that progressed on chemotherapy alone were subsequently treated with Onyx-015 in some cases; two of the four injected tumors underwent complete regressions. This data illustrates the potential of viral and chemotherapy combinations. The clinical utility of dl1520 in this indication will be de®nitively determined in a phase III randomized trial.
A phase I/II trial of dl1520 administered by hepatic artery infusion in combination with intravenous 5-uorouracil and leukovorin was carried out (n=33 total) (Reid et al., 2000) . Following phase I dose escalation, 15 patients with colorectal carcinoma who had previously failed the same chemotherapy were treated with combination therapy after failing to respond to dl1520 alone; one patient underwent a partial response and 10 had stable disease (2 ± 7+ months). Chemosensitization of colorectal liver metastases is therefore possible via hepatic artery infusions, although the magnitude and frequency of this eect remains to be determined. In contrast, data from a phase I/II trial studying the combination of dl1520 and gemcitabine chemotherapy were disappointing (n=21); the combination resulted in only two responses, and these patients had not received prior gemcitabine (Hecht et al., 2000) . Therefore, potential synergy was demonstrated with dl1520 and chemotherapy in two tumor types that supported viral replication (head and Figure 3 A staged clinical research and development approach for a replication-selective agent in cancer patients. Following demonstration of safety and biological activity by the intratumoral route, trials were sequentially initiated to study intracavitary instillation (initially intraperitoneal), intra-arterial infusion (initially hepatic artery) and eventually intravenous administration. In addition, only patients with advanced and incurable cancers were initially enrolled on trials. Only after safety had been demonstrated in terminal cancer patients were trials initiated for patients with premalignant conditions. Finally, clinical trials of combinations with chemotherapy were initiated only after the safety of dl1520 as a single agent had been documented by the relevant route of administration Figure 4 Replication of adenoviral agent (dl1520) in nucleus of squamous carcinoma cell in the head and neck region of a patient 3 days after intratumoral virus injection. The dark staining individual particles (arrow) and clusters within the nucleus (box) are adenoviral particles Oncolytic adenovirus review D Kirn neck, colorectal), but not in a tumor type that was resistant to viral replication (pancreatic).
Results from clinical trials with dl1520 (Onyx-015): Summary dl1520 has been well-tolerated at the highest practical doses that could be administered (2610 12 ± 2610 13 particles) by intratumoral, intraperitoneal, intra-arterial and intravenous routes. The lack of clinically-signi®-cant toxicity in the liver or other organs was notable. Flu-like symptoms (fever, rigors, asthenia) were the most common toxicities and were increased in patients receiving intravascular treatment. Acute in¯ammatory cytokines (especially IL-1 and IL-6) increased within 3 h following intra-arterial infusion. Neutralizing antibodies increased in all patients, regardless of dose, route or tumor type. Viral replication was documented in head and neck and colorectal tumors following intratumoral or intra-arterial administration. Neutralizing antibodies did not block antitumoral activity in head and neck cancer trials of intratumoral injection. However, viral replication/shedding into the blood was inhibited by neutralizing antibodies; intra-arterial virus was more sensitive to antibody inhibition than was intratumorally injected virus. Single agent antitumoral activity was minimal (%15%) in head and neck cancers that could be repeatedly and aggressively injected. No objective responses were documented with single agent therapy in phase I or I/II trials in patients with pancreatic, colorectal or ovarian carcinomas. A favorable and potentially synergistic interaction with chemotherapy was discovered in some tumor types and by dierent routes of administration.
Future directions: Why has dl1520 (Onyx-015) failed to date as a single agent for refractory solid tumors?
Future improvements with this approach will be possible if the reasons for dl1520 failure as a single agent, and success in combination with chemotherapy, are uncovered. Factors that are speci®c to this adenoviral mutant, as well as factors that may be generalizable to other viruses, should be considered. Regarding this particular adenoviral mutant, it is important to remember that this virus is attenuated relative to wildtype adenovirus in most tumor cell lines in vitro and in vivo, including even p53 mutant tumors (Harada and Berk, 1999; Goodrum and Ornelles, 1997; Kirn et al., 1998b; Rothmann et al., 1998; Heise et al., 2000a) . This is not an unexpected phenotype since this virus has lost critical E1B-55 kD functions that are unrelated to p53, including viral mRNA transport. This attenuated potency is not apparent with other adenovirus mutants such as dl922/947 (Heise et al., 2000a) . In addition, a second deletion in the E3 gene region (10.4/14.5 complex) may make this virus more sensitive to the antiviral eects of tumor necrosis factor; an immunocompetent animal model will need to be identi®ed in order to resolve this issue. Factors likely to be an issue with any virus include barriers to intratumoral spread, antiviral immune responses and inadequate viral receptor expression (e.g. CAR, integrins). Viral coat modi®cations may be bene®cial if inadequate CAR expression plays a role in the resistance of particular tumor types (Roelvink et al., 1999; Douglas et al., 1996) .
Future directions: improving the ecacy of replication-selective agents
Mutations in the adenoviral genome can enhance selectivity and/or potency. For example, a promising adenoviral E1A CR-2 mutant (dl922/947) has been described that demonstrates not only tumor-selectivity (based on the G1-S checkpoint status of the cell) but also signi®cantly greater antitumoral ecacy in vivo compared to dl1520 (all models tested) and even wildtype adenovirus (in a breast cancer metastasis model) (Kirn et al., 1998a) . Another very similar E1A mutant adenovirus has demonstrated replication and cytopathic eects based on the pRB status of the target cell (Fueyo et al., 2000) . Deletion of the E1B-19 kD gene (antiapoptotic bcl-2 homologue) is known to result in a`large plaque' phenotype due to enhanced speed of cell killing (Chinnadurai, 1983) . This observation has now been extended to multiple tumor cell lines and primary tumor cell cultures (Sautho et al., 2000; Medina et al., 1999) . A similar phenotype resulted from overexpression of the E3-11.6 adenovirus death protein (Doronin et al., 2000) . It remains to be seen whether these in vitro observations are followed by evidence for improved ecacy in vivo over wildtype adenovirus.
Potency can also be improved by arming viruses with therapeutic genes (e.g. prodrug-activating enzymes and cytokines) (Hermiston, 2000; Hawkins et al., 1999; Freytag et al., 1998; Wildner et al., 1999) . Viral coat modi®cations may be bene®cial if inadequate CAR expression plays a role in the resistance of particular tumor types (Roelvink et al., 1999; Douglas et al., 1996) . Improved systemic delivery may require novel formulations or coat modi®cations, as well as suppression of the humoral immune response. Determination of the viral genes (e.g. E3-region) and immune response parameters mediating ecacy and toxicity will lead to immunomodulatory strategies. Finally, identi®cation of the mechanisms leading to the potential synergy between replicating adenoviral therapy and chemotherapy may allow augmentation of this interaction (Heise et al., 2000b) . This understanding may then allow us to bolster this interaction.
Summary
Replication-selective oncolytic adenoviruses represent a novel cancer treatment platform. Clinical studies have demonstrated the safety and feasibility of the approach, including the delivery of adenovirus to tumors through the bloodstream (Heise et al., 1999b; Reid et al., 1999; Nemunaitis et al., 1999) . The inherent ability of replication-competent adenoviruses to sensitize tumor cells to chemotherapy was a novel discovery that has led to chemosensitization strategies. These data will support the further development of adenoviral agents, including second-generation constructs containing exogenous therapeutic genes to enhance both local and systemic antitumoral activity Hermiston, 2000; Agha-Mohammadi and Lotze, 2000) . In addition to adenovirus, other viral species are being developed including herpesvirus, vaccinia, reovirus and measles virus (Kirn, 2000a; Martuza, 2000; Norman and Lee, 2000; Mastrangelo et al., 2000; Coey et al., 1998; Martuza et al., 1991; Kirn, 2000b; Lattime et al., 1996) . Since intratumoral spread also appears to be a substantial hurdle for viral agents, inherently motile agents such as bacteria may hold great promise for this ®eld (Low et al., 1999; Sznol et al., 2000) .
Given the unknown predictive value of in vitro cellbased assays and murine tumor model systems for the ecacy and therapeutic index of replication-selective oncolytic adenoviruses in patients, we believe that encouraging adenoviral agents must be tested in welldesigned clinical trials as soon as possible. Only then can the true therapeutic potential of these agents be realized.
